Affimed NV (AFMD) Earns “Buy” Rating from Oppenheimer Holdings Inc.

Oppenheimer Holdings Inc. reissued their buy rating on shares of Affimed NV (NASDAQ:AFMD) in a research note issued to investors on Wednesday morning.

Separately, Zacks Investment Research cut shares of Affimed NV from a buy rating to a hold rating in a research note on Wednesday, March 22nd. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Affimed NV presently has a consensus rating of Buy and a consensus target price of $3.81.

Shares of Affimed NV (NASDAQ:AFMD) opened at 2.60 on Wednesday. The firm’s 50-day moving average is $2.30 and its 200 day moving average is $2.25. The firm’s market capitalization is $86.34 million. Affimed NV has a 52 week low of $1.65 and a 52 week high of $5.00.

WARNING: This article was originally published by Mideast Time and is owned by of Mideast Time. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at

Several hedge funds have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC bought a new stake in Affimed NV during the fourth quarter valued at approximately $1,322,000. Baker BROS. Advisors LP bought a new stake in Affimed NV during the third quarter valued at approximately $1,112,000. Finally, Muhlenkamp & Co. Inc. boosted its stake in Affimed NV by 150.8% in the third quarter. Muhlenkamp & Co. Inc. now owns 73,109 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 43,955 shares during the period. 31.37% of the stock is currently owned by institutional investors and hedge funds.

Affimed NV Company Profile

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

5 Day Chart for NASDAQ:AFMD

Receive News & Ratings for Affimed NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed NV and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2017 Mideast Time.